Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beclometasone/formoterol/glycopyrrolate - Chiesi Farmaceutici

Next Previous
Drug Profile

Beclometasone/formoterol/glycopyrrolate - Chiesi Farmaceutici

Alternative Names: BDP/FF/GB; Beclometasone dipropionate/formoterol fumarate/glycopyrrolate bromide; Beclometasone/glycopyrrolate/formoterol; CHF-5993; ICS/LABA/LAMA; Riarify; Trimbow

Latest Information Update: 22 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiasthmatics; Bronchodilators; Chlorinated steroids; Ethanolamines; Pregnadienetriols; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Muscarinic receptor antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 15 Oct 2025 Launched for Asthma (Treatment-experienced) in China (Inhalation) prior to October 2025
  • 15 Oct 2025 Launched for Asthma (Treatment-experienced) in United Kingdom (Inhalation) prior to October 2025
  • 15 Oct 2025 Preregistration for Asthma (Treatment-experienced) in USA (Inhalation) prior to October 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top